The global Dermatophytic Onychomycosis Treatment Market is predicted to reach USD 6.63 billion by 2027, exhibiting a CAGR of 7.4% during the forecast period. The rising prevalence of diabetes and incidences of chronic nail fungus infection will lead to heavy demand for dermatophytic onychomycosis treatment, which, in turn, will foster the growth of the market, it is mentioned in a report, titled “Dermatophytic Onychomycosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Product Type (Tablets and Nail Paints), By Route of Administration (Oral and Topical), By Type (Prescribed and Over-the-Counter (OTC)), By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, and Online Channels), and Regional Forecast, 2020-2027” the market size stood at USD 3.74 billion in 2019.
Request a Sample Copy of the Research Report:
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations travel bans and quarantines restaurants closed all indoor events restricted over forty countries state of emergency declared massive slowing of the IT Spending market volatility falling business confidence, growing panic among the population, and uncertainty about future.
Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
What does the Report Include?
The market report includes quantitative and qualitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers the different regions, which are contributing to the growth of the market. It includes the competitive landscape that involves leading companies and adoption of strategies by them to introduce new products, announce partnerships, and collaboration that will contribute to the growth of the market between 2020 and 2027. Moreover, the research analyst has adopted several research methodologies such as PESTEL and SWOT analysis to extract information about the current trends and industry developments that will drive the market growth in the forthcoming years.
An Overview of the Impact of COVID-19 on this Market :
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future.
For more information visit : https://www.fortunebusinessinsights.com/dermatophytic-onychomycosis-treatment-market-103310
Increasing Prevalence of Onychomycosis to Aid Expansion in North America
The market size in North America stood at USD 1.65 billion in 2019. The growth in the region is attributed to rising cases of onychomycosis in the region. The growing R&D activities will further foster the growth of the market in the region. The increasing demand for Jublia will accelerate the growth of the market in the region. Europe is predicted to witness a high growth rate during the forecast period owing to the favorable health reimbursement policies in European countries such as Italy, Spain, and the U.K. The superior distribution of OTC drugs retail pharmacies such as Walgreens, and others will enable speedy expansion of the market in Europe. According to an article published in the Journal of the European Academy of Dermatology and Venereology, the prevalence of onychomycosis in Europe is 4.3%.
Asia Pacific is expected to rise tremendously in the forthcoming years due to the new product launches. The increasing prevalence of diabetes will spur opportunities for the market in the foreseeable future. The rising geriatric population will further improve the growth prospects of the market. In addition, the rising patient awareness and developing healthcare infrastructure in emerging economies will boost the market.
The report on the Dermatophytic Onychomycosis Treatment Market Reveals:
- Future insights into the industry
- An all-encompassing study of market size;
- In-detail data on all the segments
- Evidential information about competitors and prominent players
Emergence of Topical Treatment Solutions to Augment Growth
The growing cases of liver damage in patients will lead to a high demand for the market in the near future. According to a survey conducted on dermatologists and podiatrists in the U.S. by Moberg Pharma AB in 2017, 7 out of 10 doctors avoid prescribing oral terbinafine owing to the risk of liver damage. The innovation and development of topical treatment solutions and oral anti-fungal drugsassociated with liver damage will subsequently enable speedy expansion of the market. The rising need for improved topical solutions will impel dermatologists and podiatrists to present new theories for drug enhancement, which, in turn, will augur well for the market. Moreover, the increasing adoption of nail lacquerswill consequently create new opportunities for the market during the forecast period. In addition, the increasing spending on R&D activities by major players will have a tremendous impact on the market in the foreseeable future.
Quick Buy – Dermatophytic Onychomycosis Treatment Market Research Report:
December 2019: Moberg Pharma, a Swedish pharmaceutical company announced that M0B-015, topical terbinafine under phase 3 clinical study has met the primary and secondary endpoint for the treatment of onychomycosis.
The Report Lists the Main Companies in the Dermatophytic Onychomycosis Treatment Market:
- Bausch Health Companies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc.
- Cipla Inc.
- Kaken pharmaceuticals Co., Ltd.
- Other Prominent Players